Dasatinib, even at low doses, is an effective second-line...

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

Giuseppe Visani, Massimo Breccia, Antonella Gozzini, Giorgina Specchia, Enrico Montefusco, Enrica Morra, Mario Annunziata, Andrea Camera, Francesco Cavazzini, Fabio Stagno, Patrizia Pregno, Emilio Usa
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
85
Year:
2010
Language:
english
Pages:
4
DOI:
10.1002/ajh.21871
File:
PDF, 640 KB
english, 2010
Conversion to is in progress
Conversion to is failed